Development of a Novel Anti-Adhesive Vaccine Against Targeting the C-terminal Disulfide Loop of the Pilin Protein.

Citation data:

International journal of molecular and cellular medicine, ISSN: 2251-9637, Vol: 6, Issue: 2, Page: 96-108

Publication Year:
2017
Captures 9
Readers 9
Social Media 2
Tweets 2
PMID:
28890886
DOI:
10.22088/acadpub.bums.6.2.4
Author(s):
Faezi, Sobhan; Bahrmand, Ahmad Reza; Mahdavi, Mehdi; Siadat, Seyed Davar; Nikokar, Iraj; Sardari, Soroush
Most Recent Tweet View All Tweets
article description
Type IV pili (T4P) are major virulence factors of () that are associated with primary adhesion, biofilm formation and twitching motility. This study focuses on the introduction of a novel biologically active subunit vaccine derived from the disulfide loop (DSL) of pilin. We investigated the expression of the novel PilA in-frame with pET26b vector, which contains three domains, that each domain contains three tandem repeats. The flexible (GGGGS) and (GGGGS)3 linkers were linked between the three tandem repeats and each domain, respectively. The recombinant construct (pET26b/) was transformed and expressed in BL21 (DE3). The reactivity of specific antiserum against PilA was assessed by ELISA method. The biological activities of this candidate vaccine were evaluated by western blotting, opsonophagocytosis and twitching inhibition assays. The pET26b/ plasmid was confirmed by enzymatic digestion. The purified PilA protein was confirmed by immunoblot analysis. The checkerboard titration showed that the optimal dilution of the antibody to react with antigen was 1:8. The results of opsonophagocytosis assay revealed that the antibodies raised against PilA promoted phagocytosis of the PAO1 and 6266E strains to some extent (17.5% and 16.3%, respectively), so the twitching inhibition test confirmed this result. Taken together, these are the preliminary results based on a first chimerical structure failure to induce antibodies that promote the opsonization and eradication of the pathogen. Therefore, the biological activity of the PilA protein showed that it should be introduced with other proteins or target antigens against in the future studies.